Edition:
United States

Celon Pharma SA (CLNP.WA)

CLNP.WA on Warsaw Stock Exchange

31.40PLN
17 Aug 2018
Change (% chg)

-1.60zł (-4.85%)
Prev Close
33.00zł
Open
33.10zł
Day's High
33.10zł
Day's Low
30.30zł
Volume
35,114
Avg. Vol
11,905
52-wk High
38.50zł
52-wk Low
27.88zł

Latest Key Developments (Source: Significant Developments)

Celon Pharma FY Net Profit Down At 25.6 Million Zlotys
Monday, 16 Apr 2018 02:55pm EDT 

April 17 (Reuters) - CELON PHARMA SA ::SAID ON MONDAY THAT ITS FY NET PROFIT WAS 25.6 MILLION ZLOTYS VERSUS 37.8 MILLION ZLOTYS YEAR AGO.FY REVENUE WAS 107.1 MILLION ZLOTYS VERSUS 128.8 MILLION ZLOTYS YEAR AGO.  Full Article

Celon Pharma Supervisory Board Chairman Resigns
Wednesday, 3 Jan 2018 09:38am EST 

Jan 3 (Reuters) - CELON PHARMA SA ::MACIEJ ANDRZEJ KRASINSKI RESIGNS FROM HIS POST AS CHAIRMAN OF CO'S SUPERVISORY BOARD.  Full Article

Celon Pharma To Get PLN 24.7 Mln Financing For Development Of Biosimilar Drug
Wednesday, 13 Dec 2017 08:58am EST 

Dec 13 (Reuters) - CELON PHARMA SA ::SIGNS AGREEMENT FOR FUNDING OF ITS PROJECT WITH NATIONAL CENTRE FOR RESEARCH AND DEVELOPMENT.UNDER AGREEMENT TO GET PLN 24.7 MILLION FINANCING FOR DEVELOPMENT OF BIOSIMILAR DRUG BASED ON FAB FRAGMENT.  Full Article

Celon Pharma Plans To Place Salmex On Scandinavian Markets In H1 2018
Thursday, 30 Nov 2017 05:17am EST 

Nov 30 (Reuters) - CELON PHARMA SA ::INFORMS THAT REGISTRATION PROCEDURE OF SALMEX DRUG IN SCANDINAVIAN COUNTRIES ENDS POSITIVELY.ESTIMATES THAT WILL PLACE SALMEX ON SCANDINAVIAN MARKETS IN H1 2018.  Full Article

Celon Pharma Can Start Phase I Clinical Study Of Esketamine-Based Drug
Tuesday, 28 Nov 2017 07:47am EST 

Nov 28 (Reuters) - CELON PHARMA SA ::GETS PERMISSION FOR STARTING PHASE I CLINICAL STUDY FOR ITS DRUG BASED ON ESKETAMINE.PLANS TO END PHASE I CLINICAL STUDY OF ESKETAMINE-BASED DRUG IN APRIL, 2018.  Full Article

Celon Pharma Q3 net profit down at 4.9 mln zlotys
Wednesday, 15 Nov 2017 11:34am EST 

Nov 15 (Reuters) - CELON PHARMA SA :Q3 REVENUE 24.2 MILLION ZLOTYS VERSUS 22.4 MILLION ZLOTYS YEAR AGO.Q3 NET PROFIT 4.9 MILLION ZLOTYS VERSUS 7.2 MILLION ZLOTYS YEAR AGO.  Full Article

Celon Pharma to get 25.6 mln zloty financing for its project
Friday, 10 Nov 2017 08:26am EST 

Nov 10 (Reuters) - CELON PHARMA SA ::SIGNS DEAL WITH NCBIR UNDER WHICH CO TO GET 25.6 MILLION ZLOTY FINANCING FOR ITS PROJECT.  Full Article

Celon Pharma registers its drug Salmex in Portugal
Friday, 3 Nov 2017 06:11am EDT 

Nov 3 (Reuters) - CELON PHARMA SA ::ITS DRUG SALMEX GETS REGISTERED IN PORTUGAL, CO CHECKS POTENTIAL OF MARKET AND DRUG COMMERCIALIZATION.  Full Article

Celon Pharma gets US patent on FGFR inhibitors
Wednesday, 25 Oct 2017 06:02am EDT 

Oct 25 (Reuters) - CELON PHARMA SA ::GETS US PATENT ON FGFR INHIBITORS AND THEIR USE IN MEDICINAL PRODUCTS.  Full Article

Celon Pharma H1 net profit shrinks to 13.4 mln zlotys
Thursday, 21 Sep 2017 01:23am EDT 

Sept 21 (Reuters) - CELON PHARMA SA ::SAID ON WEDNESDAY THAT ITS H1 REVENUE WAS 57.0 MILLION ZLOTYS VERSUS 71.9 MILLION ZLOTYS A YEAR AGO.H1 OPERATING PROFIT WAS 12.8 MILLION ZLOTYS VERSUS 28.2 MILLION ZLOTYS A YEAR AGO .H1 NET PROFIT WAS 13.4 MILLION ZLOTYS VERSUS 22.7 MILLION ZLOTYS .  Full Article

No consensus analysis data available.